Kisqali (Ribociclib)

Ribociclib is a medicine used to treat a common type of breast cancer, including early cancer with a high chance of coming back and cancer that has spread. It works by blocking proteins that help cancer cells divide. It's taken as a pill by mouth along with hormone therapy.

Brand names:Kisqali
Medication

What people taking Kisqali (Ribociclib) report

Every report comes from a Lived member, sent anonymously.

Have you tried Kisqali (Ribociclib) for Breast Cancer?

NameHow it went

About Kisqali (Ribociclib)

What It's For

Ribociclib, sold as Kisqali, is a prescription cancer medicine taken as a tablet by adults with hormone receptor-positive, HER2-negative breast cancer, the most common type. Hormone receptor-positive (HR-positive) means the cancer cells use estrogen or progesterone to fuel their growth. HER2-negative means the cells do not make high levels of HER2, a growth protein that some breast cancers overproduce and that calls for different treatment. It has two approved uses. In early breast cancer (stage II or III) that has a high risk of coming back, it is added to hormone therapy after surgery and other initial treatment to lower the chance of the cancer returning. In advanced breast cancer, including cancer that has spread to other parts of the body (metastatic), it is used to hold the cancer back for longer and help people live longer. Ribociclib is never used on its own. It is paired with hormone therapy: an aromatase inhibitor such as letrozole or anastrozole, which lowers the amount of estrogen the body makes, or, for advanced disease, fulvestrant, an injected medicine that blocks estrogen from acting on cancer cells. Women who have not been through menopause, and men, also receive a medicine called an LHRH (luteinizing hormone-releasing hormone) agonist, such as goserelin, to suppress the body's own sex hormone production so the hormone therapy can work fully.

How It Works

Cells divide by moving through a series of steps called the cell cycle. Two enzymes, CDK4 and CDK6 (cyclin-dependent kinases 4 and 6), act as a switch that lets a cell pass an early checkpoint and commit to dividing. Growth signals reaching a breast cancer cell, including those set off by estrogen, work partly by flipping this switch on. Ribociclib blocks CDK4 and CDK6, so cancer cells stall at that checkpoint and multiply more slowly. Hormone therapy attacks the same growth process from another direction by cutting off estrogen or blocking its effect. That is why the two are combined: in laboratory studies the pairing slowed tumor growth more than either alone, and in clinical trials the combination worked better than hormone therapy by itself. Ribociclib belongs to a group of medicines called CDK4/6 inhibitors.

Dosage & Administration

Kisqali comes as 200 mg tablets taken by mouth once a day, with or without food, at about the same time each day, preferably in the morning. Treatment runs in four-week (28-day) cycles: one dose a day for 21 days, then 7 days off before the next cycle begins. The hormone therapy partner follows its own schedule; an aromatase inhibitor, for example, is taken every day without a break. The starting dose depends on the situation. For early breast cancer it is 400 mg (two tablets) a day, and ribociclib is taken for 3 years unless the cancer returns or side effects make it necessary to stop. The aromatase inhibitor continues for longer than that, at least 5 years in the main trial. For advanced breast cancer the starting dose is 600 mg (three tablets) a day, continued for as long as it keeps the cancer under control and side effects are manageable. Swallow the tablets whole, without chewing, crushing or splitting them, and do not take a tablet that is broken or cracked. If a dose is missed, or vomited after it was taken, do not take an extra dose that day; take the next dose at the usual time. The oncology team may pause treatment or lower the dose if blood counts, liver tests or heart tracings change.

Side Effects

The most frequent effect is a drop in white blood cells, especially neutrophils, the cells that fight bacterial infections. Most people show some drop on blood tests. It usually causes no symptoms by itself and generally recovers when treatment is paused or the dose is lowered, but while counts are low, infections are more likely and can become serious. Infections, nausea, tiredness and headache are also common. At the higher dose used for advanced breast cancer, diarrhea, vomiting, constipation, hair thinning, cough, rash and back pain are common as well. Rises in liver enzymes and changes in kidney blood tests often appear on routine labs before they cause any symptoms. A few problems call for contacting the care team right away rather than waiting for the next visit. Fever, chills or other signs of infection come first, because low white cell counts can let an infection progress quickly. New or worsening cough, shortness of breath or chest pain can signal inflammation of the lungs (pneumonitis), which is uncommon but can be severe. A painful or rapidly spreading rash, blistering or peeling skin, or sores in the mouth, eyes or lips, especially with fever or flu-like symptoms, can be a rare but serious skin reaction. A fast, pounding or irregular heartbeat, dizziness or fainting can reflect the heart rhythm effect described below. Yellowing of the skin or eyes, dark urine, or pain in the upper right side of the abdomen can signal liver injury.

Interactions & Warnings

Ribociclib can lengthen the QT interval, a measurement on an electrocardiogram (ECG, a tracing of the heart's electrical activity) that reflects how long the heart takes to reset between beats. A markedly longer QT interval can set off a dangerous irregular heart rhythm. Most of this effect appears in the first four weeks. For that reason, an ECG is done before starting and again around day 14 of the first cycle, low potassium, magnesium, calcium or phosphorus is corrected first, and ribociclib is generally avoided in people with long QT syndrome or significant heart problems such as a recent heart attack, heart failure or a slow heart rhythm. That heart rhythm risk shapes the most important interactions. Ribociclib is not used with tamoxifen, another breast cancer hormone therapy, because the combination lengthened the QT interval more than either medicine did alone. Other medicines that prolong the QT interval, including some drugs for irregular heart rhythms, are avoided or closely monitored with ECGs. The liver enzyme CYP3A breaks down ribociclib, so strong blockers of it, such as ritonavir (an HIV medicine), raise ribociclib levels and its side effects, while strong boosters of it, such as rifampin (an antibiotic used mainly for tuberculosis), can leave too little ribociclib to work. Grapefruit and grapefruit juice should be avoided, and St. John's wort, an herbal supplement, can also interact. Ribociclib can in turn raise levels of some other medicines. The oncologist and pharmacist should review every prescription, over-the-counter product and supplement, and check before anything new is started. Ribociclib can harm a developing baby. Anyone who could become pregnant needs a pregnancy test before starting and effective contraception during treatment and for at least 3 weeks after the last dose, and should tell the care team right away about a known or suspected pregnancy. Breastfeeding should be avoided during treatment and for at least 3 weeks afterward. Ribociclib may also reduce fertility in men.

What to Expect

The benefit of ribociclib is measured over months and years rather than felt from day to day. In advanced breast cancer, regular scans show whether the cancer is shrinking, stable or growing. In a large trial of women past menopause starting treatment for advanced disease, adding ribociclib to letrozole extended median survival to about 64 months, compared with about 51 months on letrozole alone. In early breast cancer the goal is prevention. In the main trial, after 3 years about 91 of every 100 people taking ribociclib with an aromatase inhibitor had no return of invasive breast cancer, new invasive cancer or death, compared with about 88 of every 100 taking the aromatase inhibitor alone. Effects on overall survival in early breast cancer were not yet settled when that analysis was reported. The first months involve the most testing. Blood counts and liver tests are checked every 2 weeks for the first 2 cycles, then at the start of each of the next 4 cycles, and as needed after that. Blood minerals are checked at the start of each of the first 6 cycles alongside the early ECGs. Pauses and dose reductions for side effects are a planned part of treatment, and many people continue at a lower dose. In early breast cancer, ribociclib has a set end point at 3 years, while hormone therapy continues beyond it.

Questions to Ask Your Doctor

  1. 1.What do you expect ribociclib to add for my particular cancer, compared with hormone therapy alone?
  2. 2.Which hormone therapy will I take with it, and do I also need an injection to suppress my own hormone production?
  3. 3.Do my heart history or my current medicines and supplements make the heart rhythm risk a concern for me?
  4. 4.How often will I need blood tests and ECGs, and which symptoms should prompt a call to your team, including after hours?
  5. 5.If I have side effects, how would a pause or lower dose affect how well the treatment works?

Last reviewed • Oct 2026

Educational content, not medical advice.